Skip Nav

Contact Us

Chondrosarcoma CS Foundation, Inc.

Thank you for your interest in our company. Complete the form below to send us an email, or simply give us a call. We're looking forward to working with you.

  • 301-352-3042

    OK!

    Testing the Combination of Belinostat and SGI-110 (Guadecitabine) for the Treatment of Unresectable and Metastatic Conventional Chondrosarcoma

    June 19th, 2021SUMMARY This phase II trial studies the effect of belinostat and SGI-110 (guadecitabine) combination therapy in treating patients with conventional chondrosarcoma that cannot be removed by surgery (unresectable) and has spread to other places in...

    Read Article

    Empowering Patients to Speak Up for Your Health

    June 3rd, 2021Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer Center (mskcc.org) Transcript: Barbra Rothschild:...

    Read Article

    Article on Targeted Cancer Therapies

    May 26th, 2021Targeted Cancer Therapies ON THIS PAGE What are targeted cancer therapies? How are targets for targeted cancer therapies identified? How are targeted therapies developed? What types of targeted therapies are available? ...

    Read Article

    Empowering Patients to Speak Up for Your Health

    May 25th, 2021Check out the video hosted by Memorial Sloan Kettering entitled: Empowering Patients: Speak Up for Your Health. The link is listed below as well as the transcript. The Empowered Patient: Speak Up for Your Health | Memorial Sloan Kettering Cancer...

    Read Article

    Inhibrx Announces Positive Interim Results from the Phase 1 Trial of INBRX-109 in Chondrosarcoma Patients

    May 16th, 2021 SAN DIEGO, Nov. 11, 2020 /PRNewswire/ --InhibRx, Inc. (Nasdaq: INBX), a biotechnology company with four clinical programs in development, announced updated interim results today from a Phase 1 clinical trial evaluating the efficacy and safety of...

    Read Article

    Chondrosarcoma (CS) Foundation Celebrates It First Anniversary

    May 8th, 2021[gallery] This coming Friday will be the Chondrosarcoma Foundation’s first anniversary. Last year, on May 14, 2020 during the beginning of the pandemic, we launched the Chondrosarcoma Foundation by bringing CS Foundation web site on-line. My...

    Read Article

    Inbrx-109 Phase 1 Trial Shows Positive Interim Results in Patients with Chondrosarcoma

    May 7th, 2021November 13, 2020 Dylann Cohn-Emery Treatment with the investigation agent INBRX-109 induced responses and decreased the tumor burden in a cohort of patients with chondrosarcoma, according to interim efficacy and safety findings a phase 1 trial in...

    Read Article

    INBRX-!09 on the Fast Track for Metastatic Conventional Chondrosarcoma Patients

    May 7th, 2021Inhibrx Granted Fast Track Designation for INBRX-109 for the Treatment of Unresectable or Metastatic Conventional Chondrosarcoma Patients Registration-enabling study expected to begin dosing in the second or third quarter of this year

    Read Article
    Skip to content